A recent study from Yeshiva University has uncovered an important insight into hypertension treatment: some commonly prescribed drugs to lower blood pressure can actually raise it in certain patients.
Idorsia Pharmaceuticals has claimed FDA approval for aprocitentan as a treatment for resistant hypertension, becoming the first drug in the endothelin receptor antagonist class for that indication.